Pairx Bio

PairX is pioneering the development of next-generation cancer-selective biologics by identifying novel, highly prevalent, tumor-selective cell surface variants. Our biology-driven approach reveals a new class of therapeutic targets that can be paired with a variety of optimal therapeutic modalities. Founded on IP exclusively licensed from Duke-NUS Medical School, Singapore, PairX is advancing a robust pipeline of potential first- and best-in-class tumor-selective therapies targeting prevalent cancers in substantial patient populations.